Pharmaceuticals

Global Pharmaceuticals Native Starch Market Report 2026: Emerging Trends and Growth Scenarios

February 17, 2026February 17, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the pharmaceuticals native starch market from 2026–2035 with trusted insights from The Business Research Company

What long-term size projections exist for the Pharmaceuticals Native Starch Market covering 2026–2035?

The pharmaceuticals native starch market size has experienced strong growth in recent years. It is projected to expand from $6.11 billion in 2025 to $6.64 billion in 2026, at a compound annual growth rate (CAGR) of 8.6%. The historical growth can be attributed to factors such as the availability of natural starch sources, the expansion of generic pharmaceuticals, the widespread adoption of tablets and capsules, cost sensitivity in drug formulation, and regulatory acceptance of native starch.

The pharmaceuticals native starch market is poised for significant expansion in the foreseeable future. Its valuation is forecast to reach $9.23 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.6%. This anticipated growth is driven by various factors such as the rise of clean-label drug formulations, escalating sustainability demands, the growth of pharmaceutical manufacturing in emerging markets, an increasing need for biodegradable excipients, and advancements in starch processing. Key trends projected for this period include an expanding preference for natural and clean-label excipients, their broader application in solid oral dosage forms, increased usage as binders and disintegrants, the growth of plant-based pharmaceutical ingredients, and a greater focus on developing cost-effective excipients.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24376&type=smp

Which Drivers Are Impacting The Competitive Landscape Of The Pharmaceuticals Native Starch Market?

The growing incidence of chronic health conditions is anticipated to boost the expansion of the pharmaceuticals native starch market moving forward. Chronic diseases are defined as long-term medical ailments that typically progress slowly and persist for a year or longer. This increasing prevalence is primarily linked to the rising aging population, as elderly individuals are more susceptible to enduring health issues such as diabetes, cardiovascular diseases, arthritis, and cancer, which commonly become more widespread with age. Pharmaceuticals native starch contributes to the management of chronic diseases by enhancing drug formulation stability, improving drug bioavailability, enabling controlled drug release, supporting patient adherence, and ultimately strengthening the effectiveness and long-term care of these medical conditions. For instance, in April 2025, data from the Centers for Disease Control and Prevention, a US-based federal public health agency, revealed that 76.4% of U.S. adults, representing approximately 194 million people, reported having one or more chronic conditions in 2023, with the prevalence at 59.5% among young adults, 78.4% among midlife adults, and 93.0% among older adults. Consequently, the increasing prevalence of chronic diseases is a key factor driving the growth of the pharmaceuticals native starch market.

What Segments Are Identified Within The Structure Of The Pharmaceuticals Native Starch Market?

The pharmaceuticals native starch market covered in this report is segmented –

1) By Type: Potato Starch, Corn Starch, Other Types

2) By Formulation Type: Oral Solid Dosage Forms, Liquid Dosage Forms, Topical Formulations, Injectable Drugs, Controlled Release Formulations

3) By Functionality: Texturizing Agent, Moisture Retention Agent, Bulking Agent, Emulsifying Agent, Film-Forming Agent

4) By Application: Binders And Coating Agents, Disintegrants, Fillers And Extenders, Stabilizers, Thickening Agents

5) By End-User: Pharmaceutical Manufacturers, Contract Research Organizations (CROs), Contract Manufacturing Organizations (CMOs), Research And Development Labs, Academic Institutions, Other End-users

Subsegments:

1) By Potato Starch: Native Potato Starch (Pharmaceutical Grade), Low Moisture Native Potato Starch, Fine Particle Size Native Potato Starch, High Purity Native Potato Starch

2) By Corn Starch: Native Corn Starch (Pharmaceutical Grade), Low Moisture Native Corn Starch, Fine Particle Size Native Corn Starch, High Purity Native Corn Starch

3) By Other Types: Rice Starch, Wheat Starch, Tapioca Starch

How Are Emerging Trends Affecting The Progression Of The Pharmaceuticals Native Starch Market?

Major companies in the pharmaceuticals native starch market are prioritizing the creation of innovative products, such as plant-based textures, to enhance drug formulation and improve patient compliance. Plant-based texture refers to the physical characteristics derived from plant ingredients, including thickness and gel strength, which assists pharmaceuticals in using native starch by improving tablet binding, disintegration, and mouthfeel for better natural drug formulations. For instance, in February 2024, Ingredion Incorporated, a US-based food company, introduced Novation Indulge 2940 starch, a clean-label texturizer designed to enhance texture and stability in dairy and alternative dairy products. This advanced pharmaceutical native starch offers functional properties that elevate drug formulation performance, bioavailability, and controlled release, while also supporting the development of clean-label, sustainable products. NOVATION Indulge 2940 starch is a versatile ingredient that improves texture, stability, and consumer acceptance in both dairy and alternative dairy products, utilizing clean-label, natural ingredients.

Which Major Firms Are Strengthening Their Position In The Pharmaceuticals Native Starch Market?

Major companies operating in the pharmaceuticals native starch market are Cargill Incorporated, Archer Daniels Midland Company, Ingredion Incorporated, Roquette Frères SA, Emsland Group, Tereos SCA, AGRANA Beteiligungs-AG, Grain Processing Corporation, Universal Starch-Chem Allied Ltd., SPAC Starch Products (India) Private Limited, Sanstar Biopolymers Ltd., Gulshan Polyols Ltd., Tate & Lyle Public Limited Company, BENEO GmbH, Hungrana Kft., Bluecraft Agro Pvt. Ltd., Visco Starch, Manildra Group, Shandong Liujia Pharmaceutical Excipient Co. Ltd., Zhucheng Xingmao Corn Developing Co. Ltd.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/pharmaceuticals-native-starch-global-market-report

Which Region Shows The Strongest Potential For Future Expansion In The Pharmaceuticals Native Starch Market?

North America was the largest region in the pharmaceuticals native starch market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pharmaceuticals native starch market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Pharmaceuticals Native Starch Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24376&type=smp

Browse Through More Reports Similar to the Global Pharmaceuticals Native Starch Market 2026, By The Business Research Company

Modified Starch Market Report 2026

https://www.thebusinessresearchcompany.com/report/modified-starch-global-market-report

Industrial Starch Market Report 2026

https://www.thebusinessresearchcompany.com/report/industrial-starch-global-market-report

Starch Derivatives Market Report 2026

https://www.thebusinessresearchcompany.com/report/starch-derivatives-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795